Journal article

MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer

O ElMokh, V Taelman, P Radojewski, MA Roelli, A Stoss, RA Dumont, MS Dettmer, WA Phillips, MA Walter, RP Charles

Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2019

Abstract

Anaplastic thyroid carcinoma (ATC) is refractory to radioiodine therapy in part because of impaired iodine metabolism. We targeted the mitogen-activated protein kinase and phosphatidylinositol 3- kinase (PI3'K) pathways with the intent to induce radioiodine uptake for radioiodine treatment of ATC. Methods: Human ATC cells were used to evaluate the ability of pharmacologic inhibition of the mitogen-activated protein kinase and PI3'K pathways to induce radioiodine uptake. Thyrocyte-specific double-mutant BRAFV600E PIK3CAH1047R mice were treated with a MEK inhibitor followed by radioiodine treatment, and tumor burden was monitored by ultrasound imaging. Results: ATC cell lines showed an increas..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung


Funding Acknowledgements

Funding support was provided by Swiss National Science Foundation grant 31003A_149824/1 and Swiss National Science Foundation grant NCCR-TransCure. No other potential conflict of interest relevant to this article was reported.